Evoke Pharma Inc. (EVOK)

[subslover]

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program
June 15, 2022 08:30 ET | Source: Evoke Pharma, Inc.




...
SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Florida Medicaid Pharmaceutical & Therapeutics Committee has approved adding GIMOTI, the Company’s novel treatment solution meant to treat symptoms associated with acute and recurrent diabetic gastroparesis, to the Florida Medicaid Preferred Drug List (PDL) effective immediately.

To prescribe Gimoti under the plan, healthcare providers need to attest to the patient being at least 18 years of age, having a diagnosis of diabetic gastroparesis, and being unable to use oral metoclopramide. These criteria are typical for Gimoti coverage under state Medicaid programs and consistent with Company expectations for utility in helping patients who suffer from this debilitating disease. Patients taking oral metoclopramide are often unable to achieve relief due to a delay in gastric emptying and erratic absorption of oral medication. We believe many patients can benefit from the novel nasal delivery of Gimoti to treat symptoms such as nausea, vomiting and abdominal pain. The Florida Medicaid formulary and related programs provide healthcare to approximately 5 million beneficiaries.

With this addition, we are building a strong foundation and momentum for positive access to GIMOTI within Medicaid lives in the US. “We view this addition to the Florida Medicaid PDL as a win for patient access to this important medicine for diabetic gastroparesis patients, who have very limited options to obtain symptomatic relief. In a world where many new products are excluded from formularies and patient access is denied, this decision is a significant commercial milestone for GIMOTI,” stated Matt D’Onofrio, MBA, Evoke Pharma’s Chief Business Officer. “Medicaid approvals across various jurisdictions are one of the primary components of our business plan to increase GIMOTI access. With this addition, we believe we are steadily executing the right strategies to ensure that healthcare providers around the country have the option to make GIMOTI the standard of care for diabetic gastroparesis.”

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.

Follow GIMOTI on Facebook: https://www.facebook.com/GIMOTI-metoclopramide-nasal-spray-104672345100289
Follow Evoke Pharma on Facebook: https://www.facebook.com/Evoke-Pharma-Inc-131313647029724